ea0022p29 | Adrenal | ECE2010
Mauclere-Denost Sophie
, Leboulleux Sophie
, Borget Isabelle
, Al Ghuzlan Abir
, Young Jacques
, Drouard Laurence
, Paci Angelo
, Chanson Philippe
, Schlumberger Martin
, Baudin Eric
Background: The benefit to risk ratio of mitotane high starting dose regimen in ACC remains unknown.Methods: To evaluate a high starting dose strategy, we performed a single-center, prospective study with three main objectives: 1) to assess the time taken to reach a mitotane plasma level above 14 mg/l (benefit); 2) to evaluate mitotane tolerance (risk) in the first 3 months of treatment and 3) to analyse the correlation using a regression analysis test b...